Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4933748 | Psychiatry Research | 2017 | 11 Pages |
Abstract
Motivational enhancement therapy (MET) is efficacious in reducing cannabis use, yet benefits are generally short-lived. Oxytocin is a hypothalamic neuropeptide that promotes prosocial behaviors and plays a role in drug-related neuroadaptations; as such, oxytocin may enhance the effect of MET on cannabis outcomes. Cannabis dependent adults were randomized to receive MET plus oxytocin (n =8) or placebo (n =8). Participants receiving oxytocin showed reductions in amount of cannabis used daily and number of sessions per day. Participants receiving placebo did not evidence significant reductions. Powered clinical trials of oxytocin-enhanced MET for cannabis use disorder are warranted.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Brian J. Sherman, Nathaniel L. Baker, Aimee L. McRae-Clark,